The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Evaluating whether prior bendamustine exposure impacts the efficacy of epcoritamab in DLBCL
In this video, Tycel Phillips, MD, City of Hope, Duarte, CA, comments on the impact of prior bendamustine exposure on the efficacy of epcoritamab in patients with diffuse large B-cell lymphoma (DLBCL). Dr Phillips notes that prior bendamustine exposure does not appear to impact the efficacy of epcoritamab, unlike CAR T-cell studies, and suggests that bispecific antibodies may be a better choice for patients receiving bendamustine before a T-cell-directed therapy. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
